Core Viewpoint - Shares of Compass Diversified (NYSE: CODI) fell nearly 15% in intraday trading due to troubling accounting practices at a subsidiary, leading to a securities class action lawsuit [1] Financial Measures - Compass Diversified announced urgent liquidity measures including a forbearance agreement with lenders, reduction in management fees, and suspension of quarterly cash distributions [2] - The company will also curtail new investments in Lugano Holdings, the subsidiary involved in the controversy, to focus on its other eight portfolio companies [2] Regulatory Issues - The New York Stock Exchange notified Compass that it is out of compliance with listing requirements due to delayed quarterly report filings, facing a six-month deadline to remedy the situation or risk delisting [3] Legal Actions - A securities class action lawsuit was filed in California, alleging that Compass and executives misled investors about the financial health of Lugano Holdings, claiming undisclosed financing arrangements and irregularities in financial statements [4][5] - The lawsuit contends that Compass's internal controls were inadequate and key information was withheld from shareholders [5] Financial Impact - On May 7, Compass revealed "irregularities" in Lugano's financial practices, leading to a sell-off that erased more than half of the company's market value in one day [6] - Following this, Compass announced a delay in releasing its first-quarter 2025 financial results as an internal investigation is ongoing [6] Investigative Actions - Hagens Berman is investigating potential securities violations by Compass Diversified, indicating the severity of the financial reporting issues [7]

Core Viewpoint - Coinbase Global, Inc. experienced a significant cybersecurity incident that led to a 7% drop in share price, raising concerns about its internal controls and disclosure processes [1]. Group 1: Cybersecurity Incident - On May 15, 2025, Coinbase disclosed a material cybersecurity incident where a threat actor accessed personal information of nearly 70,000 customers [4]. - The company reported that the threat actor claimed to possess customer account information and internal documentation, allegedly obtained by paying contractors or employees to extract data from Coinbase's systems [5]. - Estimated costs for remediation and customer reimbursement could reach $400 million [5]. Group 2: Investigation and Legal Actions - Hagens Berman has initiated an investigation into potential securities law violations related to Coinbase's claims about its security measures and controls [2][3]. - The investigation is focused on whether Coinbase misrepresented its security controls and delayed disclosing the cybersecurity incident [6]. - Reports indicated that rival exchanges Binance and Kraken were targeted by similar hacks but managed to protect customer data, raising further questions about Coinbase's security adequacy [6]. Group 3: Investor Actions - Investors who suffered substantial losses are encouraged to submit their losses to assist in the investigation [2][7]. - Whistleblowers with non-public information regarding Coinbase are urged to consider their options to aid in the investigation, with potential rewards under the SEC Whistleblower program [7].

SAN FRANCISCO, May 22, 2025 (GLOBE NEWSWIRE) -- On May 21, 2025, investors in UroGen Pharma Ltd. (NASDAQ: URGN) saw the price of their shares crash 44% after the company announced that the FDA’s Oncologic Drugs Advisory Committee (“ODAC”) voted against the risk/benefit profile of UroGen’s UGN-102, a therapy intended to treat patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (“LG-IR-NMIBC”) for which no drugs are currently FDA-approved. Hagens Berman has opened an investigation in ...

Core Viewpoint - SelectQuote Inc. is facing significant investor pressure due to a sharp decline in share prices following disappointing quarterly results and ongoing legal issues related to alleged violations of the False Claims Act [1][3]. Financial Performance - For the quarter ended March 2025, SelectQuote reported earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share [2]. - The company posted revenues of $408.16 million, falling short of the Zacks Consensus Estimate of $417.01 million by 2.12% [2]. Legal Issues - The U.S. Department of Justice (DOJ) announced a lawsuit on May 1, 2025, alleging that SelectQuote and other major health insurers violated the False Claims Act in their marketing of Medicare Advantage plans [3][4]. - The lawsuit claims that from 2016 to at least 2021, SelectQuote received significant payments from insurers for Medicare Advantage enrollments, but allegedly steered beneficiaries toward higher-commission plans, disregarding their suitability [4]. Investor Sentiment - The combination of a disappointing earnings report and serious legal allegations has heightened concerns regarding SelectQuote's financial stability and operational integrity [5]. - Hagens Berman is investigating potential violations of U.S. securities laws and is encouraging investors who have suffered losses to come forward [2][5].

Core Viewpoint - Napco Security Technologies, Inc. is facing significant challenges, including a securities class action lawsuit and declining sales, which have raised concerns about its distribution network and forecasting capabilities [1][3][4]. Financial Performance - For the third quarter of fiscal year 2025, Napco reported revenue of $43.96 million, which was above Wall Street's expectations, but represented a year-on-year decline of 10.8% [2]. - The company experienced a substantial 25% drop in equipment sales in the second quarter of fiscal 2025 compared to the same period the previous year, alongside declines in gross margin and gross profit [6]. Legal Issues - A class action lawsuit has been filed against Napco, representing investors who purchased securities between February 5, 2024, and February 3, 2025, following a significant drop in stock price due to disappointing earnings disclosures [3][4]. - The lawsuit alleges that Napco made false and misleading statements regarding its sales forecasts and the ability to manage demand fluctuations, which were not disclosed to investors [4][5]. Market Reaction - Following the negative earnings report on February 3, 2025, Napco's stock price fell sharply, erasing $9.77 per share in value and prompting analysts to downgrade their ratings on the company [7]. Investigative Actions - Hagens Berman, a securities litigation firm, is investigating potential securities fraud claims against Napco, emphasizing the ongoing concerns about the company's sales performance and distribution management [8].

Core Viewpoint - A securities class action lawsuit has been filed against Compass Diversified due to the company's announcement of a restatement of its 2024 financial statements, linked to undisclosed financing arrangements and irregularities in its Lugano business unit [1][4][6] Group 1: Lawsuit Details - The lawsuit, Matthews v. Compass Diversified Holdings, LLC, seeks to represent investors who purchased Compass securities between May 1, 2024, and May 7, 2025 [1][2] - Allegations include false and misleading statements made by Compass regarding its Lugano unit, which operates in the branded consumer goods sector, and the failure to disclose critical information about financing arrangements and irregularities in sales, cost of sales, inventory, and accounts receivable [2][3] Group 2: Financial Impact - The alleged irregularities necessitated a restatement of Compass Diversified's 2024 financial statements, rendering them unreliable [3] - Following the disclosure of these issues, Compass's stock price fell by 60% in a single trading day, resulting in significant losses for shareholders [5] Group 3: Regulatory and Investigative Actions - The lawsuit claims that Compass violated the Securities Exchange Act of 1934 by making untrue statements and omitting material facts [6] - Hagens Berman, a law firm, is investigating potential securities violations by Compass and is encouraging affected investors to come forward [7][8]

SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- In a dramatic turn for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), investors watched the company's shares plunge nearly 44% on May 9, 2025, after the San Carlos-based cell therapy pioneer reported a first-quarter revenue miss that sharply contradicted earlier upbeat assurances from management. Hagens Berman is now investigating whether Iovance violated U.S. securities laws and urges Iovance investors who suffered substantial losses to submit your losses now. ...

Core Insights - Compass Diversified's stock dropped 59% following the announcement that its 2024 financial statements are no longer reliable due to irregularities at its Lugano Holding subsidiary [1][2][4] - An internal investigation into Lugano's financing and accounting practices has revealed significant irregularities, leading to a delay in the filing of the first quarter 2025 financial report and a restatement of 2024 results [2][4] - The founder and CEO of Lugano, Moti Ferder, resigned without severance amid the fallout from the investigation [3] Investigation Details - Hagens Berman is investigating potential violations of U.S. securities laws related to Compass Diversified, focusing on whether shareholders were misled [5][6] - The investigation is scrutinizing the company's disclosures and practices, particularly in light of the accounting irregularities at Lugano [6] Company Response - Compass Diversified's CEO, Elias Sabo, emphasized that the issues uncovered do not reflect the company's values and indicated a commitment to addressing the situation [4] - The company is taking steps to distance itself from the conduct of its subsidiary, Lugano [4]

SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (NASDAQ: FLNC) faces mounting challenges as disappointing fiscal second-quarter results and a steep guidance revision collide with escalating legal scrutiny over alleged financial misrepresentations. The disappointing quarter arrives amid an escalating federal securities class action lawsuit, with investors accusing Fluence of painting an overly optimistic picture of its business-and the looming May 12, 2025 deadline for lead plaintiff sta ...

Core Viewpoint - SelectQuote's share price dropped over 19% following a lawsuit filed by the U.S. Department of Justice, alleging violations of the False Claims Act related to its business practices in the Medicare Advantage market [1][3]. Group 1: Lawsuit and Allegations - The U.S. Department of Justice filed a lawsuit against SelectQuote and other insurance brokers, claiming they violated the False Claims Act [1]. - The investigation focuses on SelectQuote's disclosures regarding its sales practices, particularly in its Senior business offering Medicare Advantage plans [2]. - Allegations include that SelectQuote directed Medicare beneficiaries to plans that provided the highest kickbacks to brokers, rather than acting in the best interest of the beneficiaries [5]. Group 2: Financial Impact - Following the announcement of the lawsuit, SelectQuote's shares fell by over 19% on May 1, 2025 [1][3]. - The lawsuit raises concerns about the potential inflation of SelectQuote's financial results due to alleged steering practices [4]. Group 3: Whistleblower Information - Whistleblowers with non-public information regarding SelectQuote are encouraged to assist in the investigation, with potential rewards of up to 30% of any successful recovery made by the SEC [4].